NVZMF (Novonesis (Novozymes) B) EV-to-EBIT : 38.53 (As of May. 21, 2025)

View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Novonesis (Novozymes) B's Enterprise Value is $33,581 Mil. Novonesis (Novozymes) B's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $872 Mil. Therefore, Novonesis (Novozymes) B's EV-to-EBIT for today is 38.53.

The historical rank and industry rank for Novonesis (Novozymes) B's EV-to-EBIT or its related term are showing as below:

NVZMF' s EV-to-EBIT Range Over the Past 10 Years
Min: 17.35 Med: 25.04 Max: 48.12
Current: 38.53

During the past 13 years, the highest EV-to-EBIT of Novonesis (Novozymes) B was 48.12. The lowest was 17.35. And the median was 25.04.

NVZMF's EV-to-EBIT is ranked worse than
76.5% of 1200 companies
in the Chemicals industry
Industry Median: 17.85 vs NVZMF: 38.53

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Novonesis (Novozymes) B's Enterprise Value for the quarter that ended in Mar. 2025 was $28,538 Mil. Novonesis (Novozymes) B's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $872 Mil. Novonesis (Novozymes) B's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 3.05%.

Novonesis (Novozymes) B EV-to-EBIT Historical Data

The historical data trend for Novonesis (Novozymes) B's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B EV-to-EBIT Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

Get a 7-Day Free Trial

27.03

37.44

22.24

26.91

54.70

Novonesis (Novozymes) B Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															26.91	36.12	40.62	54.70	32.31

Competitive Comparison of Novonesis (Novozymes) B's EV-to-EBIT

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novonesis (Novozymes) B's EV-to-EBIT Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Novonesis (Novozymes) B EV-to-EBIT Calculation

Novonesis (Novozymes) B's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	33581.121	/	871.621
	=	38.53

Novonesis (Novozymes) B's current Enterprise Value is $33,581 Mil.
Novonesis (Novozymes) B's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $872 Mil.

Novonesis (Novozymes) B (OTCPK:NVZMF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Novonesis (Novozymes) B's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 )	=	EBIT	/	Enterprise Value (Q: Mar. 2025 )
	=	871.621	/	28538.04891
	=	3.05 %

Novonesis (Novozymes) B's Enterprise Value for the quarter that ended in Mar. 2025 was $28,538 Mil.
Novonesis (Novozymes) B's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $872 Mil.

Novonesis (Novozymes) B EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NSISBc:UK 0Q4U:UK NSIS B:Denmark NZM:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.